The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER).
Maria Fernandez Abad
No relevant relationships to disclose
Isabel Calvo
No relevant relationships to disclose
Noelia Martinez
No relevant relationships to disclose
Mercedes Herrero
No relevant relationships to disclose
Yolanda Quijano
No relevant relationships to disclose
Hipolito Duran
No relevant relationships to disclose
Mariola Garcia Aranda
No relevant relationships to disclose
Ana Suárez
No relevant relationships to disclose
Fernando López-Ríos
No relevant relationships to disclose
Diego Perez
No relevant relationships to disclose
Sofia Perea
No relevant relationships to disclose
Manuel Hidalgo
No relevant relationships to disclose
Laura García-Estevez
No relevant relationships to disclose